Beneficial Effects of ε-Viniferin on Obesity and Related Health Alterations
dc.contributor.author | Gómez Zorita, Saioa | |
dc.contributor.author | Milton Laskibar, Iñaki | |
dc.contributor.author | Eseberri Barace, Itziar ![]() | |
dc.contributor.author | Beaumont, Pauline | |
dc.contributor.author | Courtois, Arnaud | |
dc.contributor.author | Krisa, Stéphanie | |
dc.contributor.author | Portillo Baquedano, María Puy ![]() | |
dc.date.accessioned | 2023-02-24T15:18:01Z | |
dc.date.available | 2023-02-24T15:18:01Z | |
dc.date.issued | 2023-02-12 | |
dc.identifier.citation | Nutrients 15(4) : (2023) // Article ID 928 | es_ES |
dc.identifier.issn | 2072-6643 | |
dc.identifier.uri | http://hdl.handle.net/10810/60070 | |
dc.description.abstract | Viniferin is a phenolic compound belonging to the group of stilbenoids. In particular, ε-viniferin is a dimer of resveratrol, found in many plant genders, among which grapes (Vitis vinifera) are a primary source. Due to the fact that ε-viniferin is mainly present in the woody parts of plants, their use as a source of this bioactive compound is a very interesting issue in a circular economy. Both, in vitro studies carried out in pre-adipocytes and mature adipocytes and in vivo studies addressed in mice show that ε-viniferin is able to reduce fat accumulation. Moreover, it prevents the development of some obesity co-morbidities, such as type 2 diabetes, dyslipidemias, hypertension and fatty liver. ε-viniferin can be absorbed orally, but it shows a very low bioavailability. In this scenario, further research on animal models is needed to confirm the effects reported in a great number of studies; to determine which metabolites are involved, including the main one responsible for the biological effects observed and the mechanisms that justify these effects. In a further phase, human studies should be addressed in order to use ε-viniferin as a new tool for obesity management, as a nutraceutical or to be included in functional foods. | es_ES |
dc.description.sponsorship | This research was funded by CIBEROBN under Grant CB12/03/30007 and the Government of the Basque Country (IT1482-22). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | viniferin | es_ES |
dc.subject | obesity | es_ES |
dc.subject | glucose homeostasis | es_ES |
dc.subject | dyslipidemia | es_ES |
dc.subject | hypertension | es_ES |
dc.subject | fatty liver | es_ES |
dc.title | Beneficial Effects of ε-Viniferin on Obesity and Related Health Alterations | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2023-02-24T14:08:56Z | |
dc.rights.holder | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/2072-6643/15/4/928 | es_ES |
dc.identifier.doi | 10.3390/nu15040928 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | |
dc.departamentoeu | Farmazia eta elikagaien zientziak |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).